# Antonio Jimeno

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/antonio-jimeno/

## Facts

| Field | Value |
| --- | --- |
| Citations | 32,451 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 66 |
| i10-index | 152 |
| OpenAlex ID | https://openalex.org/A5007992309 |
| ORCID iD | https://orcid.org/0000-0001-8560-0440 |
| Works | 419 |

## Researcher papers

- [Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study](https://scholariq.org/papers/pembrolizumab-versus-methotrexate-docetaxel-or-cetuximab-for-recurrent-or/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Head and Neck Cancer Studies](https://scholariq.org/topics/head-and-neck-cancer-studies/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)
- [Hedgehog Signaling Pathway Studies](https://scholariq.org/topics/hedgehog-signaling-pathway-studies/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.